Fresenius SE & Co KGaA
XETRA:FRE

Watchlist Manager
Fresenius SE & Co KGaA Logo
Fresenius SE & Co KGaA
XETRA:FRE
Watchlist
Price: 42.75 EUR 0.54%
Market Cap: 24.1B EUR

Fresenius SE & Co KGaA
Investor Relations

Fresenius SE & Co. KGaA, a titan in the global healthcare sector, traces its origins to a humble pharmacy in Frankfurt, Germany, in 1912. Since then, the company has evolved into a multifaceted healthcare conglomerate, positioning itself prominently in four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Each segment synergizes to form a comprehensive healthcare ecosystem. Fresenius Medical Care, the crown jewel of the group, stands as the world’s leading provider of products and services for individuals with renal diseases. This division, with a focus on dialyzing patients suffering from chronic kidney failure, operates a vast network of dialysis clinics and manufactures dialysis machines and related products that account for a significant portion of its income.

Meanwhile, Fresenius Kabi, the pharmaceutical and medical device division, specializes in lifesaving drugs and technologies for critically and chronically ill patients. This division thrives on providing clinical nutrition, infusion therapy, and generics, positioning itself as a critical player in hospitals worldwide. Fresenius Helios is acknowledged as Europe's largest private hospital operator, managing a vast array of healthcare facilities that deliver inpatient and outpatient care, ensuring a steady stream of revenue through diverse healthcare services. Lastly, Fresenius Vamed provides a wide range of services for healthcare facilities, from project development and construction to full operational management, allowing the company to gain financial benefits from turnkey hospital solutions and infrastructure development. Through these concerted efforts, Fresenius SE & Co. KGaA cements its role as a key stakeholder in the global healthcare market, generating substantial revenues while addressing diverse medical needs across the globe.

Show more
Loading

Earnings Calls

2025 Q1
May 7, 2025
Show Transcript
Previous
Next
Fresenius Q1 2025: Strong Revenue Growth and Positive Margin Trends
2025 Q1
May 7, 2025

Fresenius reported a robust Q1 2025, achieving 7% organic revenue growth and 4% EBIT growth, reaffirming its full-year guidance. The Kabi division excelled with a 6% revenue increase, bolstered by biopharma’s 40% growth. The EBIT margin rose to 16.8%, driven by operational efficiencies. Helios also performed well with an 8% revenue boost, benefiting from strong activity levels. The group’s EPS grew by 12% as the company streamlined operations and reduced debt. Looking ahead, Fresenius anticipates continuous momentum, underpinned by strategic investments and improved balance sheet flexibility, positioning itself favorably in the evolving healthcare sector.

Show Full Analysis

Management

Mr. Michael Sen
CEO, President & Chairman of Management Board of Fresenius Management SE
No Bio Available
Ms. Sara Lisa Hennicken
CFO & Member of the Management Board - Fresenius Management SE
No Bio Available
Mr. Pierluigi Antonelli
Member of Management Board of Fresenius Management SE & CEO of Fresenius Kabi
No Bio Available
Dr. Michael Sven Moser Ph.D.
Member of Management Board of Fresenius Management SE
No Bio Available
Mr. Robert Moller
Member of the Management Board of Fresenius Management SE
No Bio Available
Mr. Nick Stone
Senior VP of Investor Relations & Head of Investor Relations - Fresenius Management SE
No Bio Available
Matthias Link
Senior Vice President Corporate Communications
No Bio Available
Sebastian Schlagwein
Head of Group ESG
No Bio Available

Contacts

Address
HESSEN
Bad Homburg vor der Hohe
Else-Kroener-Str. 1
Contacts
+4961726080.0
www.fresenius.com